Fampridine Medicine 10 December 2019 Extended indication Therapeutic value Possible equal value Total cost Registration phase Registration application pending Product Active substance Fampridine Domain Neurological disorders Reason of inclusion Generic G Main indication Multiple sclerosis Extended indication Current proprietary name Fampyra (Biogen) Already available biosimilars / generics Proprietary name Manufacturer Portfolio holder Mechanism of action Unknown Route of administration Unknown Therapeutical formulation Unknown Budgetting framework Unknown Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP Unknown Submission date September 2019 Expected Registration September 2020 Orphan drug Unknown Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks SPC Fampridine (Biogen) verloopt op 24-07-2026. Therapeutic value Current treatment options Therapeutic value Possible equal value This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks